Haemostasis

The Sheffield Haemostasis Research Group has active research interests in inherited and acquired defects in the haemostatic (blood clotting) system.

Current research areas:

• Initially funded by the EU project, Molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD), work on enhancing understanding of type 1 VWD continues through the EU-VWD group (chaired by Ian Peake and Francesco Rodeghiero, Vicenza) and US National Institutes for Health funding; Zimmerman program on the molecular and clinical biology of VWD (ZPMCB-VWD) with North American collaborators Bob Montgomery (Milwaukee) and David Lillicrap (Kingston, Ontario)
• The molecular basis of Glanzmann Thrombasthenia.
• The molecular basis and pathophysiology of inherited thrombocytopenia.
• The role of thrombin generation in the assessment of bleeding and thrombotic disorders.
• The monitoring of adverse events of haemophilia treatment. This project led from Sheffield is an EU funded and involves 56 partners in 27 countries.
• Defining molecular mechanisms responsible for the control of transcription in genes encoding proteins with pro- and anti-coagulant function. Studies include investigation of functional consequences of sequence variation in the promoter regions of these genes.
• In addition to extensive international collaboration, the group works closely with local NHS clinical and laboratory Coagulation colleagues (Dr Steve Kitchen), with the UK National External Quality Assessment Scheme for Blood Coagulation and with Sheffield Diagnostic Genetics Service (Dr Anne Goodeve) facilitating collaborative working between different facets of research and clinical work and enabling rapid translation of research findings into the patient pathway.